Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities

&NA; Ulcerative colitis (UC) and Crohn's disease (CD), the primary constituents of inflammatory bowel disease (IBD), are precipitated by a complex interaction of environmental, genetic, and immunoregulatory factors. Higher rates of IBD are seen in northern, industrialized countries, with greater prevalence among Caucasians and Ashkenazic Jews. Racial gaps are closing, indicating that environmental factors may play a role. IBD is multigenic, with the most clearly established genetic link between certain NOD2 variants and CD. Regardless of the underlying genetic predisposition, a growing body of data implicates a dysfunctional mucosal immune response to commensal bacteria in the pathogenesis of IBD, especially CD. Possible triggers include a chronic inflammatory response precipitated by infection with a particular pathogen or virus or a defective mucosal barrier. The characteristic inflammatory response begins with an infiltration of neutrophils and macrophages, which then release chemokines and cytokines. These in turn exacerbate the dysfunctional immune response and activate either TH1 or TH2 cells in the gut mucosa, respectively associated with CD and, less conclusively, with UC. Elucidation of immunological and genetic factors indicate multiple points at which the inflammatory cascade may be interrupted, yielding the possibility of precise, targeted therapies for IBD.

[1]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[2]  Judy H. Cho,et al.  Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease , 2002, Clinical Microbiology Reviews.

[3]  R. Farrell,et al.  Microbial factors in inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[4]  R. Pounder,et al.  Concordance rates of twins and siblings in inflammatory bowel disease (IBD) , 1998 .

[5]  J. Schölmerich,et al.  Different Subsets of Enteric Bacteria Induce and Perpetuate Experimental Colitis in Rats and Mice , 2001, Infection and Immunity.

[6]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[7]  M. Donnenberg,et al.  Pathogenic strategies of enteric bacteria , 2000, Nature.

[8]  N. Arber,et al.  Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. , 1995, Gastroenterology.

[9]  A. Ahlbom,et al.  Diet and Inflammatory Bowel Disease: A Case-Control Study , 1992, Epidemiology.

[10]  Alastair Forbes,et al.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. , 2002, Gastroenterology.

[11]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[12]  P. Mannon,et al.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.

[13]  P. Brigidi,et al.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[14]  J. Mayberry,et al.  The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second- generation South Asians in Leicester (1991-1994). , 1999 .

[15]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[16]  V. Binder,et al.  Genetic Epidemiology in Inflammatory Bowel Disease , 1998, Digestive Diseases.

[17]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[18]  C. O'Morain,et al.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.

[19]  A. Sonnenberg.  Occupational distribution of inflammatory bowel disease among German employees. , 1990, Gut.

[20]  N. Mortensen,et al.  Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. , 1996, Gut.

[21]  M. Colonna,et al.  Macrophages Expressing Triggering Receptor Expressed on Myeloid Cells-1 Are Underrepresented in the Human Intestine1 , 2005, The Journal of Immunology.

[22]  M. Cassatella.  The production of cytokines by polymorphonuclear neutrophils. , 1995, Immunology today.

[23]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[24]  I. Fuss.  Cytokine network in inflammatory bowel disease. , 2003, Current drug targets. Inflammation and allergy.

[25]  A. Algra,et al.  Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. , 1996, Gastroenterology.

[26]  S. Targan,et al.  Role of cytokines in the pathogenesis of inflammatory bowel disease. , 2000, Annual review of medicine.

[27]  J. Korzenik,et al.  Inflammatory bowel disease and environmental influences. , 2002, Gastroenterology clinics of North America.

[28]  T. Koepsell,et al.  Effects of cigarette smoking on the clinical course of ulcerative colitis. , 1988, Scandinavian journal of gastroenterology.

[29]  E. Lindberg,et al.  Smoking and inflammatory bowel disease. A case control study. , 1988, Gut.

[30]  E. Nimmo,et al.  Genetics of inflammatory bowel disease: scientific and clinical implications. , 2003, Best practice & research. Clinical gastroenterology.

[31]  S. Targan,et al.  Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. , 1993, Gut.

[32]  A. Sonnenberg.  Occupational mortality of inflammatory bowel disease. , 1990, Digestion.

[33]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[34]  L. Melton,et al.  Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. , 1996, Gastroenterology.

[35]  J. Rotter,et al.  Geographic origins of Jewish patients with inflammatory bowel disease. , 1989, Gastroenterology.

[36]  A. Young,et al.  Prokaryotic Regulation of Epithelial Responses by Inhibition of IκB-α Ubiquitination , 2000 .

[37]  W. Sandborn,et al.  Epidemiology of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[38]  M. Abreu.  The pathogenesis of inflammatory bowel disease: Translational implications for clinicians , 2002, Current gastroenterology reports.

[39]  Anders Ekbom,et al.  Epidemiology of inflammatory bowel disease. , 1999, Nestle Nutrition workshop series. Clinical & performance programme.

[40]  J. Mayberry,et al.  The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991–1994) , 1999, American Journal of Gastroenterology.

[41]  L. Friedman,et al.  Epidemiology and the natural course of inflammatory bowel disease. , 1999, Gastroenterology clinics of North America.

[42]  R. Hammer,et al.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. , 1996, The Journal of clinical investigation.

[43]  E. Lindberg,et al.  Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. , 1988, Gut.

[44]  B. Sands.  From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. , 2004, Gastroenterology.